Texas Yale Capital Corp. Takes Position in Humana Inc. (NYSE:HUM)

Key Points

• Texas Yale Capital Corp. has acquired a new position in Humana Inc., purchasing 1,350 shares valued at approximately $357,000 in the first quarter.
• Humana reported earnings of $11.58 per share, significantly exceeding analysts' expectations of $10.07, with revenues also beating forecasts at $32.11 billion.
• Institutional investors and hedge funds own approximately 92.38% of Humana's stock, indicating strong interest in the company from these entities.

Texas Yale Capital Corp. purchased a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,350 shares of the insurance provider's stock, valued at approximately $357,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Riverview Trust Co purchased a new stake in shares of Humana in the 1st quarter valued at about $34,000. Garde Capital Inc. purchased a new position in Humana during the first quarter valued at $36,000. Transce3nd LLC purchased a new position in shares of Humana in the fourth quarter worth $38,000. Whipplewood Advisors LLC increased its position in Humana by 639.1% during the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after acquiring an additional 147 shares during the last quarter. Finally, Colonial Trust Advisors grew its holdings in Humana by 4,500.0% during the fourth quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock valued at $47,000 after purchasing an additional 180 shares during the period. Institutional investors own 92.38% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on HUM. Morgan Stanley decreased their price objective on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research report on Thursday. Robert W. Baird reduced their target price on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Barclays set a $275.00 price objective on Humana and gave the stock an "equal weight" rating in a research note on Thursday. Bank of America decreased their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a report on Tuesday, June 17th. Finally, Oppenheimer upped their price target on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research note on Thursday, May 1st. Sixteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $281.62.

Humana Stock Performance

NYSE HUM traded down $9.93 on Thursday, hitting $251.55. 1,433,572 shares of the stock were exchanged, compared to its average volume of 1,738,673. The company has a market capitalization of $30.36 billion, a PE ratio of 17.80, a P/E/G ratio of 1.59 and a beta of 0.44. The business's fifty day moving average is $234.17 and its 200 day moving average is $255.74. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $382.72. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 14.47% and a net margin of 1.42%. The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the prior year, the business posted $6.96 earnings per share. Humana's revenue was up 9.6% compared to the same quarter last year. Research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.